Generic medicine

Bortezomib: Brands, Price & Uses in Bangladesh

Bortezomib is a proteasome inhibitor chemotherapy agent used in the treatment of certain blood cancers.

Forms:IV Infusion

About Bortezomib

Indications of Bortezomib

Bortezomib is a proteasome inhibitor chemotherapy agent used in the treatment of certain blood cancers. Its evidence-based indications are:

FDA-approved / Established indications

  • Multiple myeloma — Bortezomib is approved for the treatment of adult patients with multiple myeloma, including previously untreated disease (in combination with melphalan and prednisone) and relapsed/refractory disease (as a single agent or in combination regimens).
  • Mantle cell lymphoma — Bortezomib is approved for the treatment of adult patients with mantle cell lymphoma, including previously untreated disease (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone) and relapsed/refractory disease.

Combination therapy requirement

For previously untreated multiple myeloma and previously untreated mantle cell lymphoma, Bortezomib must be used as part of a combination chemotherapy regimen rather than alone; see Dosage and Administration for regimen details.

Bortezomib is used only under the supervision of a physician experienced in the use of cancer chemotherapy.

Dosage & Administration of Bortezomib

Multiple myeloma — previously untreated

Bortezomib 1.3 mg/m² in combination with oral melphalan and prednisone, given as a 9-cycle (approximately 54-week) regimen: twice weekly (Days 1, 4, 8, 11) with a 10-day rest during Cycles 1-4, then once weekly (Days 1, 8, 22, 29) during Cycles 5-9.

Multiple myeloma — relapsed/refractory

Bortezomib 1.3 mg/m² given twice weekly (Days 1, 4, 8, 11) followed by a 10-day rest period (Days 12-21), constituting one 21-day treatment cycle, alone or in combination regimens as directed by the treating oncologist.

Mantle cell lymphoma — previously untreated

Bortezomib 1.3 mg/m² twice weekly (Days 1, 4, 8, 11) followed by a 10-day rest, for up to 6 cycles, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP regimen).

Mantle cell lymphoma — relapsed/refractory

Bortezomib 1.3 mg/m² twice weekly (Days 1, 4, 8, 11) followed by a 10-day rest period, as a single agent.

Dose modification for toxicity

ToxicityAction
Grade 3 non-hematologic or Grade 4 hematologic toxicityWithhold Bortezomib until toxicity resolves; resume at a 25% reduced dose
New or worsening peripheral neuropathyDose or schedule modification per established grading (see Precautions and Warnings)

Renal impairment

No initial dosage adjustment of Bortezomib is required for mild-to-severe renal impairment. In patients on hemodialysis, Bortezomib should be administered after the dialysis procedure.

Hepatic impairment

Patients with mild hepatic impairment require no dose adjustment. Patients with moderate or severe hepatic impairment should be started at a reduced dose of approximately 0.7 mg/m² in the first cycle, with consideration for subsequent dose escalation to 1.0 mg/m² or further reduction to 0.5 mg/m² based on tolerability.

Bortezomib must be prepared and administered only by healthcare professionals experienced with cytotoxic chemotherapy, in a facility equipped to manage complications. See Administration and Reconstitution for route-of-administration details.

Side Effects of Bortezomib

Adverse effects associated with Bortezomib range from very common to rare but serious:

Very common

  • Peripheral neuropathy (sensory, sometimes painful; can be dose-limiting and may be irreversible in some patients)
  • Thrombocytopenia and other cytopenias (anemia, neutropenia)
  • Nausea, vomiting, diarrhea, constipation, decreased appetite
  • Fatigue, asthenia, fever

Common

  • Hypotension, including orthostatic (postural) hypotension
  • Herpes zoster reactivation
  • Rash and other skin reactions

Rare but serious

  • Acute diffuse infiltrative pulmonary disease and other pulmonary toxicity
  • Posterior reversible encephalopathy syndrome (PRES)
  • Tumor lysis syndrome, particularly in patients with high tumor burden
  • Acute liver failure/hepatotoxicity
  • Cardiac disorders, including heart failure

Patients should promptly report new neurological symptoms, unusual bleeding or bruising, dizziness/fainting, shortness of breath, or signs of infection to their physician.

Contraindications of Bortezomib

Bortezomib is contraindicated in:

  • Patients with known hypersensitivity to Bortezomib, boron, or mannitol, including anaphylactic reactions.
  • Intrathecal administration — Bortezomib must never be given by this route; fatal outcomes have occurred when proteasome inhibitors were mistakenly given intrathecally.

Frequently Asked Questions about Bortezomib

What is Bortezomib used for?

Bortezomib is a targeted chemotherapy medicine used to treat adults with multiple myeloma and mantle cell lymphoma, two types of blood cancer. It is often combined with other chemotherapy drugs depending on the specific treatment plan.

How is Bortezomib given?

Bortezomib is given by a healthcare professional as an intravenous (IV) injection or a subcutaneous (SC) injection, never as a pill and never into the spinal fluid (intrathecally), as intrathecal administration of Bortezomib has been fatal. Your oncology team will determine the exact schedule and route for you.

What are the most important side effects of Bortezomib to watch for?

The most important effects to watch for with Bortezomib are numbness, tingling, or pain in the hands or feet (peripheral neuropathy), easy bruising or bleeding due to low platelet counts (thrombocytopenia), dizziness or fainting from low blood pressure, new shortness of breath or cough, and signs of shingles (herpes zoster) reactivation such as a painful rash. Report any of these to your doctor immediately.

Can Bortezomib be used during pregnancy or breastfeeding?

Bortezomib can cause harm to an unborn baby and should be used in pregnancy only if clearly needed, with the potential benefit outweighing the potential risk, and only under close physician guidance; effective contraception is recommended during and for several months after treatment. Breastfeeding should be avoided during Bortezomib treatment and for at least 2 months after the last dose, as it is not known whether Bortezomib passes into breast milk. Always consult your physician.

Who should not receive Bortezomib?

Bortezomib should not be given to anyone with a known hypersensitivity (allergy) to Bortezomib, boron, or mannitol, and it must never be administered intrathecally (into the spinal fluid) under any circumstances, as this has caused fatal outcomes.

What happens if too much Bortezomib is given?

An overdose of Bortezomib can cause severe low blood pressure and dangerously low platelet counts, and has been fatal in some cases. If an overdose is suspected, seek immediate medical attention or contact emergency services, as there is no specific antidote and supportive hospital care is required.

Disclaimer

The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.

DoctorBlogArticles